Pharmaceutical Nootropics CAS 87913-26-6 Bromantane Powder

As a "chip" in the pharmaceutical field, the API industry is ushering in positive changes this year. Previously, it was affected by the changes in the global supply chain pattern and the impact of downstream customers' destocking, and the supply and demand of the plate were under pressure. Since 2024, with the basic completion of overseas warehouses and the intensive arrival of API patent cliffs, the variety and number of generic drugs have risen rapidly, bringing huge opportunities to the API market.
At present, the marginal improvement in the demand side of the industry is obvious, and the output in the first two months of 2024 is 546,000 tons, although it is down 7.6% year-on-year, it has exceeded the scale of the same period in 2022, and the improvement is still continuing. On the supply side, the marginal improvement trend of API prices is emerging, although the overall price level is still lower than the historical average since 2014, but with the gradual increase in downstream procurement demand, the space for further repair of API prices is expected to open.
Following a 3-4 year downward cycle for heparin apis, prices for most are now at historically low levels. With the improvement of the global production capacity pattern, the recovery of the demand for hospital preparations, the recovery of the growth of diagnosis and treatment volume and other factors, the industry is expected to usher in the overall price and performance inflection point, among which the cost performance advantages of high-tech and high barriers of characteristic apis and fundamental reversal expectations are getting market attention. Among them, heparin, as a commonly used anticoagulant drug, will continue to improve the supply and demand relationship driven by the aging population and the increase in cardiovascular and cerebrovascular diseases, and the demand for heparin raw materials is expected to pick up in 2024. According to Frost & Sullivan forecast, the global heparin API market is expected to reach 6.199 billion US dollars in 2027, with a compound annual growth rate of 17.19%.
With the basic completion of overseas storage, it is currently at the end of the heparin cycle. The export price of heparin apis has fallen from $15,800 / kg in June 2021 to $5,500 / kg in February 2024, and the price margin has initially appeared. It is expected that a new round of heparin price upward cycle is expected to start in the second half of 2024, which is good for heparin API related head enterprises.
Previously affected by the decline in sales and destocking of heparin raw materials, a number of heparin companies performed poorly in 2023. The three companies, which are regarded as the "three strong domestic heparin apis", have a total pre-loss of about 2 billion yuan in 2023. Among them, a leading company as a global supplier of heparin raw materials has suffered a net profit loss for the first time since 2006, with a loss of 783 million yuan in 2023.
In the face of the downturn in the heparin industry, the head enterprises on the one hand continue to cultivate internal skills, consolidate sales channels and production base; On the other hand, it is transforming other high-end preparations to smooth out the impact of falling prices on performance. Taking the heparin leader as an example, the proportion of the pharmaceutical business in total revenue has increased from 21.39% in 2018 to 57.04% in the first half of 2023.
In contrast, another global leader in the heparin industry chain is one of the few domestic heparin API manufacturers that have passed the US FDA and EU EDQM certification at the same time. In recent years, it has actively transformed to the direction of high-end preparations, in addition to the Chinese market, its sterile injections are mainly sold to the United States and Europe and other international markets. The company's short-term heparin API business is subject to cyclical product impacts; In the long run, the proportion of heparin in the company's revenue and profit has declined year by year. With the rapid growth of the company's pharmaceutical business, the impact of heparin API cycle fluctuations on the company's performance is expected to gradually fade. As of the close on April 24, the company's PE (TTM) was 20.26 times, which is at the 8.59% sub-point since the listing, which is in the historical bottom range.